| CAS NO: | 1262041-49-5 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 1262041-49-5 |
| Canonical SMILES | O=C(C1=NC=CC(N2C=C(C3CC3)N=C2)=C1)NC4=CC=CC(C5=NN=CN5C6CC6)=C4 |
| 分子式 | C23H21N7O |
| 分子量 | 411.46 |
| 溶解度 | DMSO : 15.5 mg/mL (37.67 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | ASK1-IN-1 is an apoptosis signal regulating kinase 1 (ASK1) inhibitor extracted from patent WO2016025474A1, Compound 4. ASK1-IN-1 dose-dependently decreases pulmonary arterial pressure and right ventricular (RV) hypertrophy in an in vivo model of pulmonary hypertension (PH). ASKl inhibition reduces hallmarks of pulmonary vascular disease including and not limited to reduce pulmonary vascular resistance (PVR), improve pulmonary pressure, decreased pulmonary vascular remodeling, improved vascular function, decrease maladaptive RV hypertrophy, and improve RV function. Inhibition of ASKl signaling may slow, prevent, and/or reverse pathological changes associated with PH. Plasma levels of B-type natriuretic peptide (BNP) are reduced by both doses of ASK1-IN-1: 0.1+0.05 for 0.1% and 0.1±0.1 ng/mL for 0.2%. Su/Hx rats treated with 0.1 % or 0.2% ASK1-IN-1 has a decreased number of completely muscularized arterioles (35.6% and 32.6%, respectively)[1]. References: |
m.cnreagent.com